(ASCO) July 25, 2018 - A new “frailty index” predicts overall survival for patients newly diagnosed with multiple myeloma, according to a study published on July 25 in JCO Clinical Cancer Informatics (JCO CCI). This tool is important because frailty is a critical factor in treatment decision-making for many patients with multiple...

(Morningstar) July 11, 2018 - Takeda Pharmaceutical Company Limited today announced that the randomized, Phase 3 TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral NINLARO® (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival (PFS) versus placebo.